Scarica l'app Stockscreener
130.17
0.80%
1.03
Dopo l'orario di chiusura:
129.80
-0.37
-0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$129.14
Aprire:
$131.88
Volume 24 ore:
2.09M
Relative Volume:
0.98
Capitalizzazione di mercato:
$17.26B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-38.28
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
+8.61%
1M Prestazione:
+48.60%
6M Prestazione:
+25.32%
1 anno Prestazione:
+209.19%
Intervallo 1D:
$125.51
$131.88
Intervallo di 1 settimana:
$118.81
$133.97
Portata 52W:
$40.35
$133.97
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
130.17 | 17.12B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Guardant Health Coverage Assumed by Wolfe Research at Outperform - Moomoo
GH Assumed by Wolfe Research -- Rating Set to Outperform - GuruFocus
This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday - Benzinga
Guardant Health (NASDAQ: GH) director settles 154 RSUs, holds 19,516 shares - Stock Titan
Wolfe Research initiates Guardant Health stock with outperform rating By Investing.com - Investing.com Canada
3 Reasons GH is Risky and 1 Stock to Buy Instead - Yahoo Finance
Guardant Health, Inc. (GH) Stock Analysis: Navigating the Rapid Growth in Precision Oncology - DirectorsTalk Interviews
Blood testing is now included in screening recommendations for colon and rectal cancer - WQOW
Guardant Health Reaches New 52-Week High of $133.70 - Markets Mojo
Guardant Health director sells $130,060 of common stock - Investing.com UK
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Guardant Health director sells $130,060 of common stock By Investing.com - Investing.com Australia
Guardant Health (GH) director sells 1,000 shares, retains 639 - Stock Titan
Guardant Health stock hits 52-week high at 133.97 USD By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $130 to $135 - Moomoo
Guardant Health stock hits 52-week high at 133.97 USD - Investing.com
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders - Yahoo Finance
Guardant Health Insider Sold Shares Worth $1,250,836, According to a Recent SEC Filing - Moomoo
Guardant Health Stock Rockets 40% With 8-Day Winning Streak - Trefis
8-Day Rally Sends Guardant Health Stock Up 40% - Trefis
Guardant Health CLO John Saia sells $1.25 million in shares By Investing.com - Investing.com Australia
Guardant Health CLO John Saia sells $1.25 million in shares - Investing.com
Guardant Health (GH) legal chief sells 10,000 shares in open-market trades - Stock Titan
Guardant Health (NASDAQ: GH) notice: proposed sale of 1,000 shares - Stock Titan
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $130 to $160 - Moomoo
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting - BioSpace
Stifel reiterates Guardant Health stock rating on screening outlook - Investing.com
Stifel reiterates Guardant Health stock rating on screening outlook By Investing.com - Investing.com Canada
Blood tests for cancer: 38 Guardant studies at 2026 ASCO meeting - Stock Titan
Guardant Health Stock Rockets 34% With 7-Day Winning Streak - Trefis
Guardant Health Stock On Fire: Up 34% With 7-Day Winning Streak - Trefis
Why This Medtech Stock Just Bulled Through A Buy Point - Investor's Business Daily
Baron Health Care Fund Q1 2026 Portfolio Activity - Seeking Alpha
Guardant Health climbs as FDA-related momentum and an analyst price-target hike fuel gains - Quiver Quantitative
Sector Update: Health Care Stocks Mixed Premarket Wednesday - Moomoo
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines - 01net
Sector Update: Healthcare - Moomoo
Blood test added to US colorectal cancer screening options - Reuters
New blood test added to help screen 50M Americans for colorectal cancer - Stock Titan
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Guardant Health Stock Surges 26%, With A 6-Day Winning Spree - Trefis
Guardant Health Stock On Fire: Up 26% With 6-Day Winning Streak - Trefis
Guardant Health CCO Chris Freeman sells $2.9m in company stock By Investing.com - Investing.com South Africa
Guardant Health CCO Chris Freeman sells $2.9m in company stock - Investing.com Australia
Guardant Health Insider Sold Shares Worth $2,896,360, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) CCO exercises options, sells 24,406 common shares - Stock Titan
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $155 - Moomoo
BTIG raises Guardant Health stock price target on FDA approval By Investing.com - Investing.com Canada
BTIG raises Guardant Health stock price target on FDA approval - Investing.com
Guardant Health, Inc. (GH) Stock Analysis: 48.3% Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Guardant gets FDA nod for next-gen cancer mutation blood test - Mugglehead Investment Magazine
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):